MiMedx Group Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MiMedx Group Inc (MDXG)
MiMedx Group Inc stock price live, this page displays NASDAQ MDXG stock exchange data. View the MDXG premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the MiMedx Group Inc real time stock price chart below.
What Is the MiMedx Group Inc Stock Price Today?
The MiMedx Group Inc stock price today is 3.88.
What Is the Stock Symbol for MiMedx Group Inc?
The stock symbol for MiMedx Group Inc is "MDXG."
What Stock Exchange Does MiMedx Group Inc Trade On?
MiMedx Group Inc is listed and trades on the NASDAQ stock exchange.
Is MiMedx Group Inc a Good Stock to Buy?
Determining whether MiMedx Group Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDXG quote. (ISIN: US6024961012)
What Is the MiMedx Group Inc Stock Price Today?
The MiMedx Group Inc stock price today is 3.88.
What Is the Stock Symbol for MiMedx Group Inc?
The stock symbol for MiMedx Group Inc is "MDXG."
What Stock Exchange Does MiMedx Group Inc Trade On?
MiMedx Group Inc is listed and trades on the NASDAQ stock exchange.
Is MiMedx Group Inc a Good Stock to Buy?
Determining whether MiMedx Group Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDXG quote. (ISIN: US6024961012)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.79
3.99
52 wk Range
3.02
7.97
MDXG is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.793.99
52 wk Range
3.027.97
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MDXG Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
7.00
Upside
+80.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
MiMedx settles patent dispute for $25M license deal- Investing.com
- MiMedx Group Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.00
(+80.41% Upside)
MiMedx Group Inc SWOT Analysis
Market Dynamics | Explore MIMEDX's position in the $3.9 billion Advanced Wound Care and Surgical Markets, with projected growth in skin substitutes segment to $2.0 billion by 2026 |
Financial Resilience | Delve into MIMEDX's robust financial health, with 83.4% gross margin and 10.9% revenue growth, despite market challenges and regulatory headwinds |
Clinical Excellence | Learn about MIMEDX's product differentiation, supported by over 50 publications showcasing strong clinical results, including a 97% wound closure rate for DFUs |
Strategic Outlook | Discover MIMEDX's strategic initiatives, including new product launches and market expansion, with analyst targets around $11.00 per share |
MiMedx Group Inc Earnings Call Summary for Q3/2026
- Q3 revenue of $62.3M missed estimates by 9.16%, down 45% YoY; adjusted EPS of -$0.01 vs. $0.00 expected; shares fell 8.68% after-hours to $3.61.
- Adjusted EBITDA turned positive at $2M vs. -$8M in Q2; gross margin improved to 80% from 69% sequentially; company ended quarter debt-free with $121M cash.
- Surgical sales rose 9% YoY to $40M with mid-teens volume growth; wound care sales plunged 71% YoY to $22M due to Medicare reimbursement changes.
- FY2026 revenue guidance of $250M-$260M; Q4 expects high single-digit surgical growth, mid-single-digit wound care sequential growth, and modest EBITDA improvement.
- Sanara MedTech acquisition pending FTC review; combined entity expected to generate ~$400M revenue with $20M+ cost synergies and 20%+ EBITDA margin post-close.
Last Updated: 2026-10-28, 05:20 p/m
Read Full TranscriptEarnings
Latest Release
Oct 28, 2026
EPS / Forecast
-0.01 / --
Revenue / Forecast
62.28M / 68.56M
Compare MDXG to Peers and Sector
Metrics to compare | MDXG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDXGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −29.5x | 19.6x | −0.3x | |
PEG Ratio | 0.20 | −0.20 | 0.00 | |
Price/Book | 2.7x | 2.4x | 2.6x | |
Price / LTM Sales | 1.9x | 2.4x | 2.8x | |
Upside (Analyst Target) | 80.4% | 27.2% | 66.4% | |
Fair Value Upside | Unlock | 14.7% | 9.1% | Unlock |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company’s wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company’s products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the MiMedx (MDXG) Stock Price Today?
The MiMedx stock price today is 3.88 USD.
What Stock Exchange Does MiMedx Trade On?
MiMedx is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for MiMedx?
The stock symbol for MiMedx is "MDXG."
What Is the MiMedx Market Cap?
As of today, MiMedx market cap is 566.19M USD.
What Is MiMedx's Earnings Per Share (TTM)?
The MiMedx EPS (TTM) is -0.13.
When Is the Next MiMedx Earnings Date?
MiMedx will release its next earnings report on Mar 03, 2027.
From a Technical Analysis Perspective, Is MDXG a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has MiMedx Stock Split?
MiMedx has split 0 times.
How Many Employees Does MiMedx Have?
MiMedx has 808 employees.
What is the current trading status of MiMedx (MDXG)?
As of Nov 01, 2026, MiMedx (MDXG) is trading at a price of 3.88 USD, with a previous close of 3.88 USD. The stock has fluctuated within a day range of 3.79 USD to 3.99 USD, while its 52-week range spans from 3.02 USD to 7.97 USD.
What Is MiMedx (MDXG) Price Target According to Analysts?
The average 12-month price target for MiMedx is 7.00 USD, with a high estimate of 8 USD and a low estimate of 6 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +80.41% Upside potential.
What Is the MDXG Premarket Price?
MDXG's last pre-market stock price is 4.22 USD. The pre-market share volume is 910.00, and the stock has decreased by 0.25, or 6.30%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.